All In Biotech

Drug Trial Radar · NCT06754462

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

A Phase 2b, Multicenter, Double-blind, Placebo-controlled Randomized Withdrawal Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat, ACPA-Positive Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jan 10, 2025

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Immunovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
Dec 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA).

Conditions

  • Rheumatoid Arthritis

Interventions

  • IMVT-1402Drug

    Administered once weekly by subcutaneous injection.

  • PlaceboDrug

    Administered once weekly by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who maintain ACR20 response at Week 28Time frame: Week 28

Locations

83 sites in 11 countries. Site status is shown where the registry gives one.

  • Site Number - 1018

    Mesa, Arizona

  • Site Number - 1019

    Sun City, Arizona

  • Site Number - 1022

    Covina, California

  • Site Number - 1028

    San Leandro, California

  • Site Number - 1024

    Temecula, California

  • Site Number - 1033

    Tujunga, California

  • Site Number - 1023

    Whittier, California

  • Site Number - 1020

    Denver, Colorado

  • Site Number - 1015

    Jupiter, Florida

  • Site Number - 1002

    Miami, Florida

  • Site Number - 1027

    Plantation, Florida

  • Site Number - 1005

    Winter Park, Florida

  • Site Number - 1012

    Zephyrhills, Florida

  • Site Number - 1001

    Gainesville, Georgia

  • Site Number - 1034

    Chicago, Illinois

  • Site Number - 1006

    Cumberland, Maryland

  • Site Number - 1007

    Hagerstown, Maryland

  • Site Number - 1031

    Rockville, Maryland

  • Site Number - 1008

    Worcester, Massachusetts

  • Site Number - 1021

    Saint Clair Shores, Michigan

  • Site Number - 1030

    Kansas City, Missouri

  • Site Number - 1010

    Summit, New Jersey

  • Site Number - 1004

    Charlotte, North Carolina

  • Site Number - 1035

    Statesville, North Carolina

  • Site Number - 1000

    Duncansville, Pennsylvania

  • Site Number - 1016

    Jackson, Tennessee

  • Site Number - 1026

    Memphis, Tennessee

  • Site Number - 1029

    Murfreesboro, Tennessee

  • Site Number - 1037

    Allen, Texas

  • Site Number - 1017

    Colleyville, Texas

  • Site Number - 1036

    Katy, Texas

  • Site Number - 1014

    Mesquite, Texas

  • Site Number - 1013

    Tomball, Texas

  • Site Number - 1025

    Tomball, Texas

  • Site Number - 5003

    Buenos Aires, Argentina

  • Site Number - 5001

    Buenos Aires, Argentina

  • Site Number -5004

    Buenos Aires, Argentina

  • Site Number - 5002

    Buenos Aires, Argentina

  • Site Number - 5005

    Buenos Aires, Argentina

  • Site Number - 5000

    San Miguel de Tucumán, Argentina

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.